NOVOsyn® for Trocar Incision After Laparoscopic Appendectomy and Cholecystectomy
Launched by AESCULAP AG · Jul 25, 2019
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
The bacteriostatic and bactericidal effect of Novosyn® CHD will be assessed by the incidence of surgical site infection (SSI) in each suture group until 30 days postoperatively. The frequency of infections (SSI: A1 and A2) is considered as a suitable parameter for the assessment of efficacy. It is expected that the use of the Novosyn® CHD suture will reduce the occurrence of infections (SSI: A1 and A2) 30 days postoperatively compared to Novosyn suture (primary objective). SSI will be classified according to the Centre of Disease Control and Prevention (CDC), therefore the time point for as...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing a primary emergency or early elective (24h - 7 days) laparoscopic appendectomy or cholecystectomy.
- • Written informed consent
- • Age≥ 18 years
- • Not incapacitated patient
- Exclusion Criteria:
- • Open surgery for appendectomy or cholecystectomy
- • Pregnancy
- • Allergy or hypersensitivity to chlorhexidine
- • Intraoperatively conversion from laparoscopic to open surgery
- • Patients taking medical consumption that might affect wound healing
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leonberg, Baden Württemberg, Germany
Schwäbisch Hall, Baden Württemberg, Germany
Badalona, , Spain
Barcelona, , Spain
Sevilla, , Spain
Patients applied
Trial Officials
Markus Golling, Prof. Dr.
Principal Investigator
Diakonie Klinikum gGmbH Schwäbisch Hall
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials